MOTS-c

MOTS-c is a 16-amino-acid peptide derived from mitochondrial 12S rRNA, noted for its role in various metabolic processes and potential health benefits. Research suggests that it may improve insulin sensitivity and exhibit anti-aging effects through specific cellular mechanisms.

II. What is this compound?

MOTS-c, also known as Mitochondrial Open Reading Frame of the 12S rRNA-c, is classified as a mitochondrial-derived peptide (MDP) encoded by the mitochondrial genome. This peptide consists of a sequence of 16 amino acids and has a molecular weight of approximately 2174.5 Da. It was initially identified in the context of mitochondrial function and cellular metabolism, revealing its significant implications for health and disease.

The discovery of MOTS-c emerged from studies exploring mitochondrial peptides' roles in regulating cellular processes and their potential therapeutic effects. As a product of the mitochondrial genome, MOTS-c highlights the intricate relationship between energy metabolism and health, and researchers have synthesized it for various preclinical studies to explore its mechanisms and effects on metabolic health and aging.

III. How it works

MOTS-c appears to exert its effects through several key mechanisms of action. One primary mechanism involves the activation of the AMPK (AMP-activated protein kinase) signaling pathway, which is crucial for improving insulin sensitivity. Research indicates that enhancing AMPK activity may lead to improvements in glucose uptake and lipid metabolism, suggesting potential benefits for metabolic disorders [PMID: 25565208, PMID: 27060479].

Additionally, MOTS-c has been shown to inhibit the folate cycle and de novo purine biosynthesis, which may lead to altered cellular energy states and metabolic reprogramming [1] PMID: 25565208 . Furthermore, the peptide may facilitate the nuclear translocation of signaling molecules that regulate metabolic genes, thereby impacting gene expression related to energy homeostasis and metabolism [2] PMID: 27060479 .

• Activation of AMPK signaling pathway improving insulin sensitivity
  PMID 25565208PMID 27060479
• Inhibition of folate cycle and de novo purine biosynthesis
  PMID 25565208
• Nuclear translocation and transcriptional regulation of metabolic genes
  PMID 27060479

IV. Research Findings

Research surrounding MOTS-c has unveiled several promising benefits related to metabolic health and aging. Preclinical evidence suggests that MOTS-c may enhance metabolic health through its effects on insulin sensitivity and glucose metabolism, potentially leading to improved outcomes in obesity and related disorders [PMID: 25565208, PMID: 27060479]. Moreover, studies indicate that MOTS-c may possess anti-aging properties, although most research has been conducted in animal models, highlighting the need for further human studies to validate these effects [3] PMID: 27060479 .

Additionally, there is preclinical indication that MOTS-c could assist in fat loss, which may further contribute to its metabolic health benefits [4] PMID: 25565208 . However, it is essential to approach these findings with caution, as they arise from preclinical research, and more extensive clinical studies are required to confirm the relevance of these effects in human populations.

• metabolic-health preclinical
  PMID 25565208PMID 27060479
• anti-aging preclinical
  PMID 27060479
• fat-loss preclinical
  PMID 25565208

V. Dosage Context Explained

In experimental settings, MOTS-c has been administered in dosages ranging from 5 to 15 mg/kg/day via subcutaneous routes. These dosages were primarily assessed in animal models, including studies focusing on obesity and aging in mice [5] PMID: 25565208 . It is critical to note that these findings are contextual and primarily applicable to research environments. Human dosage regimens have yet to be established, and higher-level clinical evidence is required before considering specific dosing guidelines for human use.

• Administration Routes

  subcutaneous

  Range

  5–15 mg/kg/day

  animal models (mouse obesity and aging studies)

  PMID 25565208

VI. Side Effects: Research Context

Reported side effects of MOTS-c in preclinical research are currently undocumented, suggesting a favorable safety profile in animal studies. However, theoretical contraindications exist, particularly concerning active malignancies, due to potential metabolic reprogramming effects. It is important to underscore that these findings stem from preclinical models, and thus, the anecdotal accounts or unobserved effects in humans remain speculative until further evidence is generated.

• none documented in preclinical models

VII. Frequently Asked Questions